A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

NCT07128121 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV) Infection

Interventions

BIOLOGICAL: Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)
BIOLOGICAL: Placebo

Sponsor

Shenzhen Shenxin Biotechnology Co., Ltd